Your first week on Mounjaro: what actually happens

The decision you're really making at day one

Starting a new medicine always involves a decision: do I push through the early discomfort, or does this not feel right? Week one on Mounjaro is almost entirely about that question. The first pen contains 2.5 mg (the lowest available strength) and its job is to reduce the chance of nausea, not to produce the weight loss you've read about in the trial data. Think of it as the adjustment window rather than the treatment window.

That framing matters, because people who stop in week one often do so for reasons that would have resolved by week two or three. The timeline for Mounjaro to work is measured in weeks to months, and clinicians at nume see this pattern regularly. Understanding what week one is for helps you make a clearer decision about whether to continue.

Tirzepatide, the active ingredient in Mounjaro, activates two gut-hormone receptors: GLP-1 and GIP. Slowing gastric emptying is part of how it reduces appetite, and that same mechanism is why nausea can appear early, before your body finds its equilibrium. The full Mounjaro overview covers the mechanism in more detail if you want the broader picture.

What your body is likely doing in days one to seven

The most commonly reported experience in week one is mild nausea, often in the hours after the injection rather than all day. Some people also notice loose stools, burping, or a general feeling of fullness that arrives sooner than usual at mealtimes. According to NHS guidance on tirzepatide, these gastrointestinal effects are the most frequently reported side effects, and they tend to be most pronounced after starting or after a dose increase, so week one is often the hardest week on that front.

A significant proportion of people report noticeably less appetite within the first few days. Others feel nothing different at all in week one, which is equally normal at 2.5 mg. Neither experience predicts how well the medicine will work long-term.

On the weight side, any loss in week one is mostly water and reduced food volume. The meaningful, sustained fat loss that characterises Mounjaro's clinical results takes longer. The one-month weight loss picture gives a more realistic benchmark than the first seven days.

Injection technique matters here too. The pen goes into the abdomen, thigh or upper arm, rotating sites each week. Your Patient Information Leaflet covers the exact steps, and your prescriber is the right person to ask if anything about the injection itself feels uncertain.

How to make week one more manageable

There are practical things that tend to help. Smaller meals reduce the likelihood that nausea compounds the normal early fullness. Staying well hydrated matters, because vomiting or diarrhoea can cause dehydration quickly. Many people find that injecting in the evening means any nausea peaks during sleep. None of these are dosing instructions; they are habits that patients and prescribers regularly discuss together.

What you eat in week one is worth thinking about. High-fat, rich meals tend to worsen nausea in people whose gastric emptying has slowed. Leaning towards lighter, protein-adequate meals in the first week gives your system less to object to.

If you're wondering how week one compares with what comes next, the week two experience tends to be where the appetite reduction becomes more consistent for most people. By week three, many patients report the early side effects have largely settled.

One practical note: when your pen arrives (via DPD in plain, unbranded packaging) it needs to go straight into the fridge. It is stored between 2 and 8°C; your PIL gives the exact window for room-temperature use on travel days. Keep it in its original packaging away from the freezer shelf.

When to speak to a prescriber in week one

Most week-one symptoms are mild and transient. A few warrant contact with your prescriber sooner. Severe or persistent vomiting, significant abdominal pain that radiates to the back, signs of an allergic reaction (swelling, breathing difficulties, rash), or any symptom that feels out of proportion to what you expected: these are reasons to seek help promptly rather than waiting it out.

The MHRA's guidance on GLP-1 medicines, updated in early 2026, specifically highlights acute pancreatitis as a rare but serious risk: severe stomach pain reaching through to the back, with or without vomiting, needs urgent medical assessment. Suspected side effects can be reported directly at the MHRA's Yellow Card scheme.

At nume, our prescribers are available seven days a week for aftercare questions, that includes week one queries. The contact page has the direct routes. If your first week raises questions you weren't expecting, reaching out early is always the right call. And if week one leaves you wondering what the full journey looks like, by week four the picture becomes considerably clearer. When you're ready to discuss whether Mounjaro is the right step, our prescribers offer a free consultation with same-day clinical review.